



Lastacast® (olopatadine) – New over-the-counter approval

- On December 10, 2021, the [FDA approved](#) over-the-counter (OTC) use of Allergan's [Lastacast \(olopatadine\)](#) 0.25% ophthalmic solution, to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander.
 - Previously, Lastacast was available as [prescription](#) for the prevention of itching associated with allergic conjunctivitis.
- Patients should stop use of OTC Lastacast if they experience eye pain, changes in vision, increased redness of the eye, or itching that worsens or lasts for more than 72 hours.
- The recommended dosage regimen for Lastacast in adults and children 2 years of age and older is 1 drop in the affected eye(s) once daily.
- Allergan's launch plans for OTC Lastacast are pending. Lastacast will be available as a 0.25% ophthalmic solution.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.